| Field | Specification |
|---|---|
| Target | |
| Alternative names | CG-200745 formic |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C25H35N3O6 |
| Purity | |
| SMILES | |
| Form | Oil |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Ivaltinostat formic, also known as CG-200745 formic, is an orally active, potent pan-HDAC inhibitor whose hydroxamic acid moiety binds zinc at the base of the catalytic pocket. It inhibits deacetylation of histone H3 and tubulin, drives accumulation of p53 with p53-dependent transactivation, and raises expression of MDM2 and p21 (Waf1/Cip1). It also increases the sensitivity of Gemcitabine-resistant cells to Gemcitabine and 5-Fluorouracil (5-FU), inducing apoptosis and producing anti-tumor effects[1][2][3]. It is supplied as a light yellow to yellow oil (C25H35N3O6, MW 473.56) at 98.04% purity.
Physical & Chemical Properties
| CAS Number | 3078712-42-9 |
|---|---|
| Molecular Formula | C25H35N3O6 |
| Molecular Weight | 473.56 g/mol |
| Purity | 98.04% |
| Appearance | Oil |
| Color | Light yellow to yellow |
| SMILES | OC=O.O=C(NCCCN(C)C)/C(COC1=C2C=CC=CC2=CC=C1)=C/CCCCC(NO)=O |
| Target | HDAC |
| Signaling Pathway | Cell Cycle/DNA Damage; Epigenetics; Apoptosis |
| Solubility | In Vitro: DMSO: 50 mg/mL (105.58 mM; Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) H2O: 50 mg/mL (105.58 mM; Requires sonication) |
| Storage | 4°C, sealed storage, away from moisture. In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 50 mg/mL (105.58 mM) | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
| H2O | 50 mg/mL (105.58 mM) | requires sonication |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); sealed storage, away from moisture; avoid repeated freeze-thaw cycles.
If water is used as the stock solvent, dilute to the working solution and sterilize it through a 0.22 μm filter before use.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | ≥ 2.5 mg/mL (5.28 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.5 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Protocol 2
| Composition | 10% DMSO + 90% (20% SBE-β-CD in saline) |
|---|---|
| Result | ≥ 2.5 mg/mL (5.28 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.5 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 900 μL 20% SBE-β-CD in saline. 20% SBE-β-CD in saline: dissolve 2 g SBE-β-CD powder in 10 mL saline until clear (4°C, store up to one week). |
Protocol 3
| Composition | 10% DMSO + 90% Corn Oil |
|---|---|
| Result | ≥ 2.5 mg/mL (5.28 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.5 mg/mL (saturation not determined). Use with caution if continuous dosing will exceed two weeks. For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 900 μL corn oil. |
Direct preparation of the working solution
These formulations are prepared directly, without a DMSO stock; use them promptly after preparation.
Protocol 4
| Composition | PBS |
|---|---|
| Result | 50 mg/mL (105.58 mM); clear solution; requires sonication |
Data provided by the manufacturer.
In Vitro
Ivaltinostat (CG-200745; 0.01-100 μM; 48 hours) formic suppresses the growth of LNCaP, DU145 and PC3 prostate cancer cells. Ivaltinostat (1, 10 μM; 24, 48 hours) formic raises the sub-G1 population and activates caspase-9, -3 and -8[2]. Proliferation of cholangiocarcinoma cells is blocked by Ivaltinostat (0.001-100 μM; for 72 hours), with IC50s of 0.63, 0.93, and 1.80 μM for SNU-1196, SNU-1196/GR, SNU-308 cells, respectively[3]. Ivaltinostat (0-10 μM; 48 hours) formic lowers Calu6 cell proliferation to 40% of that of untreated cells[4]. Ivaltinostat (3 μM; 1-24 hours) formic significantly raises the proportion of Calu6 cells in G2/M phase (69%)[4]. At low concentration, Ivaltinostat (0-10 μM; 1-24 hours) formic treatment significantly increases histone H3 and H4 acetylation at various sites in Calu6 cells, in a time-dependent manner up to 24 hours after treatment[4].
Cell Proliferation Assay[4]
| Cell Line | Calu6 cells |
|---|---|
| Concentration | 0-10 μM |
| Incubation Time | 48 hours |
| Result | Reduced the cell proliferation to 40% of untreated cells. |
Cell Cycle Analysis[4]
| Cell Line | Calu6 cells |
|---|---|
| Concentration | 3 μM |
| Incubation Time | 1, 8, 12, 24 hours |
| Result | Increased significantly cell proportion in G2/M phase (69%). |
Western Blot Analysis[4]
| Cell Line | Calu6 cells |
|---|---|
| Concentration | 3 μM |
| Incubation Time | 1, 4, 8, 12, 24 hours |
| Result | Increased the acetylation of histone H3 and H4 at various sites in a time-dependent manner. |
In Vivo
Ivaltinostat (CG-200745; p.o.; 30 mg/kg/day; for 7 days) formic reduces oxidative stress, inflammatory cytokines, and adhesion molecules in UUO kidneys[5].
| Animal Model | Male 8-week-old C57BL/6 J mice weighing 20~22 g of unilateral ureteral obstruction (UUO)[5] |
|---|---|
| Dosage | 30 mg/kg |
| Administration | PO; daily; for 7 days |
| Result | Attenuated oxidative stress, inflammatory cytokines and adhesion molecules in UUO kidneys. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
